PDUFA VIII: Reading the FY27 Dear Colleague Letter as a Submission Volume Forecast

The Letter Most Sponsors Skim

On May 4, 2026, the FDA distributed the FY 2027 PDUFA Dear Colleague Letter. Most regulatory operations teams open it, scan the fee schedule on page two, file it for the finance team's reference, and move on.

The fee schedule is the wrong reason to read this letter. It is the publicly visible artifact of a much larger negotiation between the agency and industry over what the next PDUFA cycle is going to fund, what review timelines are going to look like, and what the agency is going to be able to commit to operationally for the next five years.

Read it that way and the letter is a forecast. The teams that build their 2027 submission planning around that forecast operate with a planning advantage over the teams that don't.

What PDUFA Actually Funds

The Prescription Drug User Fee Act, in its current iteration, funds roughly two-thirds of the human drug review program at FDA. That is not a marginal contribution — it is the operational foundation. The fees the agency collects from sponsors fund reviewer headcount, IT modernisation, post-marketing surveillance infrastructure, and the engagement programs (Type B meetings, Type C meetings, written response only) that most regulatory teams interact with regularly.

When PDUFA is reauthorised every five years, the negotiation determines three things that matter:

How many reviewers will be hired or retained. How much new technology infrastructure will be built. What new performance commitments the agency will make on review timelines, meeting response times, and decision letter quality.

The Dear Colleague Letter for any given fiscal year is the agency's annual update on how that funding is being deployed. The FY27 letter is particularly informative because PDUFA VIII negotiations are the backdrop. What the agency commits to in FY27 is, in effect, the foundation of the next reauthorisation.

What to Look For in the FY27 Letter

Three things are worth reading carefully.

The performance metrics breakdown. The agency reports on whether it met its prior-year commitments on first-cycle review actions, advisory committee turnaround, and meeting response times. The trend in those numbers tells you whether the review system is operating with capacity headroom or under stress. A center that is missing its commitments on first-cycle actions is a center that, at the margin, has less capacity to absorb extra Information Requests, more reason to issue Complete Response Letters when a submission is borderline, and longer wait times for Type B meetings.

The fee structure changes. Fee shifts between application categories, supplements, and program fees signal where the agency is allocating resources. A meaningful jump in supplement fees, for example, suggests the agency is investing in supplement review capacity — which is good news for sponsors with planned label expansions, but also signals that the agency expects supplement volume to grow.

The new initiative spend. The letter typically calls out specific programmatic initiatives funded by user fees in the upcoming year. Modernisation projects, new pilot programs, additional review divisions, and infrastructure investments all show up here. The cumulative direction of these initiatives over multiple years tells you where the agency thinks the field is going.

Translating the Forecast to Planning

The FY27 letter, read against the FY26 and FY25 letters, gives you three planning inputs.

Capacity at the division level. If the centers most relevant to your therapeutic area are running with thin capacity headroom, your submission timing strategy needs to account for it. Filing in a busy quarter at a center under capacity stress is a different exercise than filing in a quieter quarter at a center with headroom. Reviewers under load tend to issue more Information Requests, hold tighter to existing precedent, and have less appetite for novel arguments.

Modernisation pace. The technology and process improvements being funded in FY27 will land sometime in the FY27 review cycle. Sponsors filing late in FY27 will be reviewed against tooling and processes that were not available to sponsors who filed early. This is rarely a dramatic difference, but for teams that are tuning their submissions to current agency expectations, the difference matters.

Engagement program changes. New meeting types, expanded scope on existing meeting types, and changes to written-response-only programs all get telegraphed in PDUFA letters before they get formalised in guidance. Sponsors that read the signal and adjust their engagement strategy accordingly get more value from their meetings.

The Submission Volume Question

There is one specific signal worth tracking across PDUFA letters: the agency's expectation of submission volume.

The agency's volume expectations drive its hiring plans, its IT investments, and its commitment levels. When the agency expects a busy year, it staffs accordingly. When it staffs for a busy year and the year is moderate, the system runs with capacity headroom. When it staffs for a moderate year and the year turns out to be busy, the system runs hot.

For 2026 and 2027, the volume signals are mixed. Cell and gene therapy submissions continue to grow. Targeted protein degraders are reaching the agency at a steadier pace. The orphan drug designation pipeline is wider than it was three years ago. Whether the agency is staffing ahead of that curve is the central question for FY27.

The Dear Colleague Letter is the most public source of signal on that question. Worth ten minutes of careful reading once a year. Worth more than that once you have read three or four of them in a row and can see the trends emerge.

The Practical Habit

The cleanest practical habit is to read the Dear Colleague Letter on the day it lands, alongside the prior two years' letters, with a single focus: what changed. New initiatives. New fee structures. New performance metrics. Shifts in expected volume.

Then take ninety minutes to update your 2027 submission timing assumptions. That ninety minutes, run once a year, will compound into one of the more underrated planning advantages a regulatory operations team can have.